[go: up one dir, main page]

WO2018193090A3 - Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci - Google Patents

Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci Download PDF

Info

Publication number
WO2018193090A3
WO2018193090A3 PCT/EP2018/060185 EP2018060185W WO2018193090A3 WO 2018193090 A3 WO2018193090 A3 WO 2018193090A3 EP 2018060185 W EP2018060185 W EP 2018060185W WO 2018193090 A3 WO2018193090 A3 WO 2018193090A3
Authority
WO
WIPO (PCT)
Prior art keywords
intermediates
preparation
eliglustat hemitartrate
eliglustat
hemitartrate
Prior art date
Application number
PCT/EP2018/060185
Other languages
English (en)
Other versions
WO2018193090A2 (fr
Inventor
Kanaram Hanumanprasad KUMAWAT
Brijesh Rajendrakumar PATEL
Nilesh Mansukhlal Thumar
Joseph Prabahar UPADHYAY
Joseph Prabahar Koilpillai
Virendrakumar Agarwal
Parva Yogeshchandra Purohit
Arif Badrulhusan Siddiqui
Krushnakant Natvarbhai PATEL
Vipul Veljibhai GONDALIYA
Ankit Ramjibhai BUHA
Original Assignee
Amneal Pharmaceuticals Company Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amneal Pharmaceuticals Company Gmbh filed Critical Amneal Pharmaceuticals Company Gmbh
Publication of WO2018193090A2 publication Critical patent/WO2018193090A2/fr
Publication of WO2018193090A3 publication Critical patent/WO2018193090A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci. Elle concerne également des compositions pharmaceutiques stables à forme amorphe d'hémitartrate d'eliglustat comprenant la forme amorphe d'hémitartrate d'eliglustat, ainsi que leurs utilisations.
PCT/EP2018/060185 2017-04-21 2018-04-20 Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci WO2018193090A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721014151 2017-04-21
IN201721014151 2018-03-05

Publications (2)

Publication Number Publication Date
WO2018193090A2 WO2018193090A2 (fr) 2018-10-25
WO2018193090A3 true WO2018193090A3 (fr) 2019-01-03

Family

ID=62111029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/060185 WO2018193090A2 (fr) 2017-04-21 2018-04-20 Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci

Country Status (1)

Country Link
WO (1) WO2018193090A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ625712A (en) 2009-11-27 2016-02-26 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
CN110759885B (zh) * 2018-07-27 2021-10-22 中国医学科学院药物研究所 制备光活依格鲁特的方法
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
EP3941917A4 (fr) * 2019-03-22 2022-12-21 Piramal Pharma Limited Procédé amélioré pour la préparation d'éliglustat et de son intermédiaire
CN116120274A (zh) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101558A1 (fr) * 2003-05-13 2004-11-25 F. Hoffmann-La Roche Ag 2-imidazo-benzothiazoles constituant des ligands du recepteur de l'adenosine
US7615753B2 (en) * 2003-12-30 2009-11-10 Commissariat A L'energie Atomique Radiation detecting system with double resetting pulse count
WO2011066352A1 (fr) * 2009-11-27 2011-06-03 Genzyme Corporation Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0211379B8 (pt) 2001-07-16 2021-05-25 Genzyme Corp síntese de inibidores de udp-glicose: n-acil-esfingosina glicosiltransferase
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
WO2016001885A2 (fr) 2014-07-03 2016-01-07 Dr. Reddy’S Laboratories Limited Forme amorphe d'hémitartrate d'eliglustat
CN105646442A (zh) 2015-10-27 2016-06-08 北京凯莱天成医药科技有限公司 一种依利格鲁司他的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101558A1 (fr) * 2003-05-13 2004-11-25 F. Hoffmann-La Roche Ag 2-imidazo-benzothiazoles constituant des ligands du recepteur de l'adenosine
US7615753B2 (en) * 2003-12-30 2009-11-10 Commissariat A L'energie Atomique Radiation detecting system with double resetting pulse count
WO2011066352A1 (fr) * 2009-11-27 2011-06-03 Genzyme Corporation Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"/1 -(C) FILE REGISTRY RN -2138286-91-4 REGISTRY ED -Entered STN: 02 Nov 2017 CN -Octanamide, N-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxo-1-(1- pyrrolidinylmethyl)ethyl]-(CA INDEX NAME) MF -C23 H34 N2 O4 SR -Chemical Catalog Supplier: Enamine LLC LC -STN Files: CHEMCATS", 2 November 2017, article CHEMICAL ABSTRACTS OHIO: "/1 -(C) FILE REGISTRY RN -2138286-91-4 REGISTRY ED -Entered STN: 02 Nov 2017 CN -Octanamide, N-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxo-1-(1- pyrrolidinylmethyl)ethyl]-(CA INDEX NAME) MF -C23 H34 N2 O4 SR -Chemical Catalog Supplier: Enamine LLC LC -STN Files: CHEMCATS", XP055491732 *

Also Published As

Publication number Publication date
WO2018193090A2 (fr) 2018-10-25

Similar Documents

Publication Publication Date Title
PH12018500034A1 (en) Bicyclic lactams and methods of use thereof
WO2018193090A3 (fr) Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci
EP4071149A3 (fr) Composés hétérocycliques et leurs utilisations
AU2018258581A8 (en) RAF-degrading conjugate compounds
WO2015110897A3 (fr) Nouveau procédé de préparation de dolutégravir et de ses sels pharmaceutiquement acceptables
MY200328A (en) Kinase inhibitors and uses thereof
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
MX393879B (es) Métodos de preparación de niraparib.
WO2015191945A3 (fr) Formes solides de sofosbuvir
WO2014125506A3 (fr) Procédé de préparation d'ivacaftor et de ses intermédiaires
WO2016038542A3 (fr) Formes polymorphes de sofosbuvir
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
EP4339192A3 (fr) Composés et compositions pour le traitement du cancer
EA201691741A1 (ru) Фармацевтическая композиция
EA033314B1 (ru) АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ
WO2018125880A8 (fr) Activateur de nrf2
EP3615205A4 (fr) Procédé de préparation d'éthanol deutéré à partir de d2
WO2016024284A3 (fr) Processus de préparation du mirabegron et de ses produits intermédiaires
WO2015095659A3 (fr) Composition de dispersion solide d'indirubine
CA3073766A1 (fr) Procede de preparation de tubulysines et d'intermediaires de celles-ci
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
WO2016063289A3 (fr) Compositions de comprimé pharmaceutique comprenant de la rifaximine
WO2018211324A8 (fr) Promédicaments pour traiter une maladie
EP4582145A3 (fr) Formes à l'état solide de citrate d'ixazomib
AU2016250265A8 (en) (S)-2'-vinyl-abscisic acid derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18721974

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18721974

Country of ref document: EP

Kind code of ref document: A2